PRESS RELEASE published on 09/09/2025 at 11:30, 10 months 21 days ago Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47% Berenberg initiates coverage on Eckert & Ziegler SE with a "Buy" recommendation and €24 price target, highlighting market position and rising demand for radioisotopes in nuclear medicine Buy Recommendation Eckert & Ziegler SE Nuclear Medicine Berenberg Radioisotopes
BRIEF published on 08/08/2025 at 07:50, 11 months 22 days ago Eckert & Ziegler Reports Earnings Growth in First Half of 2025 Financial Results Profit Growth Medical Segment Isotope Products 2025 Forecast
PRESS RELEASE published on 08/08/2025 at 07:45, 11 months 22 days ago Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025 Eckert & Ziegler SE reports a further increase in earnings in the first half of 2025, with sales of €148.8 million and net income of €21.4 million. Confirmed forecast for 2025: sales around €320 million and EBIT around €78 million Sales Increase Earnings Eckert & Ziegler SE Medical Segment 2025 Forecast
BRIEF published on 08/05/2025 at 11:55, 11 months 25 days ago Eckert & Ziegler Announces Share Split Effective August 2025 Liquidity Frankfurt Stock Exchange Share Split Nuclear Medicine Bonus Shares
PRESS RELEASE published on 08/05/2025 at 11:50, 11 months 25 days ago Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025 Eckert & Ziegler SE implements share split, issuing bonus shares effective August 15, 2025, tripling tradable shares for improved liquidity without changing shareholder percentages Liquidity Share Split Dividend Rights Eckert & Ziegler SE Bonus Shares
BRIEF published on 07/29/2025 at 14:05, 1 year ago Eckert & Ziegler Chosen for Manufacturing Archeus’ ART-101 Radiopharmaceutical Clinical Trial Manufacturing Agreement Radiopharmaceuticals Prostate Cancer ART-101
PRESS RELEASE published on 07/29/2025 at 14:00, 1 year ago Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101 Eckert & Ziegler chosen as US manufacturer for Archeus' ART-101 radiopharmaceutical, targeting prostate cancer. Collaboration to support Phase 1 trial with state-of-the-art facility in Boston, MA Eckert & Ziegler Prostate Cancer Radiopharmaceutical ART-101 Archeus
BRIEF published on 07/28/2025 at 14:35, 1 year ago Eckert & Ziegler Completes Capital Increase, Prepares Share Split Liquidity Eckert & Ziegler Capital Increase Share Split Nuclear Medicine
PRESS RELEASE published on 07/28/2025 at 14:30, 1 year ago Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation. Eckert & Ziegler SE increases capital and prepares for share split, aiming to enhance share liquidity and trading. Leading in isotope-related components for nuclear medicine and radiation therapy Liquidity Eckert & Ziegler Capital Increase Share Split Isotope-related Components
BRIEF published on 07/15/2025 at 14:05, 1 year ago Eckert & Ziegler's Training Program Recognized for Excellence Training Excellence Berlin Chamber Award Trainee Retention Career Prospects Future Applications
Published on 07/31/2026 at 01:39, 5 hours 29 minutes ago Transition from OTCQB to Unsponsored OTC Quotation
Published on 07/30/2026 at 23:45, 7 hours 23 minutes ago Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Published on 07/30/2026 at 23:01, 8 hours 7 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Published on 07/30/2026 at 23:00, 8 hours 8 minutes ago Eagle Plains Announces Approval of Warrant Expiry Extension
Published on 07/30/2026 at 18:45, 12 hours 23 minutes ago First Canadian Graphite Reports High-Grade Graphite Prospecting Results up to 43.4% Cg at Lac Guéret South Project
Published on 07/31/2026 at 06:30, 38 minutes ago A successful first half of 2026 sets the stage for the second half
Published on 07/31/2026 at 06:30, 38 minutes ago Executing the strategy and strengthening the market position
Published on 07/31/2026 at 06:30, 38 minutes ago Strong first half with 11.5% organic growth in recurring EBIT, guidance upgraded
Published on 07/31/2026 at 06:30, 38 minutes ago HENSOLDT doubles order intake in the first half of 2026 – revenue and earnings rise significantly
Published on 07/31/2026 at 00:00, 7 hours 8 minutes ago EQS-Adhoc: VIB Vermögen AG: Agreements on the restructuring of financial liabilities of BRANICKS Group AG signed, incl. commitment for a € 60 mn financing for VIB Vermögen AG
Published on 07/30/2026 at 18:15, 12 hours 53 minutes ago Publication of the 2026 half-year financial report
Published on 07/30/2026 at 18:00, 13 hours 8 minutes ago PR ICADE – ACQUISITION OF A CONTROLLING INTEREST IN COMET
Published on 07/30/2026 at 18:00, 13 hours 8 minutes ago GUILLEMOT CORPORATION: 2026 first-half turnover / Strong consumer demand and a second half with a strong lineup of major product launches